Resorbable Scaffold Promotes Spinal Cord Injury Healing
By HospiMedica International staff writers Posted on 14 May 2018 |

Image: The Neuro-Spinal scaffold (Photo courtesy of InVivo Therapeutics).
A novel bioresorbable polymer scaffold placed within a spinal cord injury (SCI) site provides structural support to the spared spinal tissue, and a supportive matrix to facilitate endogenous repair processes.
The InVivo Therapeutics (Cambridge, MA, USA) Neuro-Spinal scaffold is a highly porous device designed to mitigate tissue damage resulting from some of the critical patho-physiological events that occur during the acute phase of SCI, including increase in tissue pressure, hemorrhage, and edema. The scaffold is composed of two biocompatible, bioresorbable polymers, Polylactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL), a positively charged polymer conducive to cellular attachment and neurite outgrowth.
The scaffold is trimmed and fitted in the epicenter of the SCI, where it modulates the healing process by providing biocompatible and cellular-adhesive appositional healing, similar to the function of sutures or a butterfly bandage in a skin laceration. It then degrades over several weeks. A study that examined the objective performance of the scaffold in 19 SCI patients showed conversion from complete paraplegia to incomplete injury within six months in 44% of the patients, exceeding the 25% conversion criterion. The study was presented at the American Association of Neurological Surgeons (AANS) annual meeting, held during May 2018 in New Orleans (LA, USA).
“At the time of stabilization surgery, a decompression laminectomy was done at the site of injury and the maximal damage was determined by ultrasonography,” said study presenter Stuart Lee, MD, of Vidant Health (Greenville, NC, USA). “Surgeons exposed the contusion through durotomy/myelotomy, used gentle irrigation to remove the necrotic tissue, and exposed the intramedullary cavity. As a side note, this gave us an opportunity to look at the pathology of acute SCI in humans, something that is generally only possible at autopsy.”
Large, multinational natural history databases consistently indicate that only 12-16% of subjects with complete thoracic injury will convert to an improved American Spinal Injury Association Impairment Scale (AIS) grade by six months after injury.
Related Links:
InVivo Therapeutics
The InVivo Therapeutics (Cambridge, MA, USA) Neuro-Spinal scaffold is a highly porous device designed to mitigate tissue damage resulting from some of the critical patho-physiological events that occur during the acute phase of SCI, including increase in tissue pressure, hemorrhage, and edema. The scaffold is composed of two biocompatible, bioresorbable polymers, Polylactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL), a positively charged polymer conducive to cellular attachment and neurite outgrowth.
The scaffold is trimmed and fitted in the epicenter of the SCI, where it modulates the healing process by providing biocompatible and cellular-adhesive appositional healing, similar to the function of sutures or a butterfly bandage in a skin laceration. It then degrades over several weeks. A study that examined the objective performance of the scaffold in 19 SCI patients showed conversion from complete paraplegia to incomplete injury within six months in 44% of the patients, exceeding the 25% conversion criterion. The study was presented at the American Association of Neurological Surgeons (AANS) annual meeting, held during May 2018 in New Orleans (LA, USA).
“At the time of stabilization surgery, a decompression laminectomy was done at the site of injury and the maximal damage was determined by ultrasonography,” said study presenter Stuart Lee, MD, of Vidant Health (Greenville, NC, USA). “Surgeons exposed the contusion through durotomy/myelotomy, used gentle irrigation to remove the necrotic tissue, and exposed the intramedullary cavity. As a side note, this gave us an opportunity to look at the pathology of acute SCI in humans, something that is generally only possible at autopsy.”
Large, multinational natural history databases consistently indicate that only 12-16% of subjects with complete thoracic injury will convert to an improved American Spinal Injury Association Impairment Scale (AIS) grade by six months after injury.
Related Links:
InVivo Therapeutics
Latest Surgical Techniques News
- Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery
- LED-Based Imaging System Could Transform Cancer Detection in Endoscopy
- New Surgical Microscope Offers Precise 3D Imaging Using 48 Tiny Cameras
- First-Of-Its-Kind Drug Illuminates Nerve Tissue for Faster and Safer Surgery
- Neuroform Atlas Stent-Assisted Coiling Found Effective Even in Smaller Arteries
- New Surgical Technique Safely Removes Giant Nerve Tumors
- Breakthrough Polymer Significantly Improves Safety of Implantable Medical Devices
- First-Ever Technology Makes Blood Translucent During Surgery
- Tibia Nailing System with Novel Side-Specific Nails to Revolutionize Fracture Surgery
- New Imaging Probe to Transform Brain Cancer Surgery
- New Technology More Than Doubles Success Rate for Blood Clot Removal
- Surgical Ablation During CABG Improves Survival in Patients with Preexisting Atrial Fibrillation
- New Battery Technology Delivers Additional Power to Implantable Medical Devices
- New Model Reveals Optimal Positioning of Orthopedic Screws in Fractures
- Non-Invasive Tool for Removing Lung Cancer Tumors Reduces Surgical Trauma
- Advanced Imaging Endoscopes to Revolutionize Detection and Treatment of Gastrointestinal Disorders
Channels
Critical Care
view channel
Skin-Like Sensor Monitors Vital Signs and Tracks Healing After Surgery
Medical conditions such as bladder control issues and the need for monitoring vital signs after surgery require precise, long-term tracking to improve patient outcomes. These conditions can be challenging... Read more
Wireless Implant Delivers Chemotherapy Deep into Tumors Without Side Effects
Solid tumors, such as those found in cancer patients, present a significant challenge in treatment due to their dense cellular structure and high interstitial pressure. Traditional drug therapies often... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read moreBusiness
view channel
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more